Title (en) KETAMINE FORMULATIONS

Title (de) KETAMINFORMULIERUNGEN

Title (fr) FORMULATIONS DE LA KETAMINE

Publication EP 2932971 A1 20151021 (EN)

Application EP 15000954 A 20060306

Priority • US 65820705 P 20050304 • EP 06736872 A 20060306

Abstract (en) Formulations of ketamine for administration to the inner or middle ear.

IPC 8 full level A61K 31/54 (2006.01); A61K 9/08 (2006.01); A61K 9/51 (2006.01); A61K 31/445 (2006.01); A61L 31/00 (2006.01)

CPC (source: EP) A61K 9/0046 (2013.01); A61K 9/06 (2013.01); A61K 31/453 (2013.01); A61L 31/16 (2013.01); A61P 27/16 (2018.01); A61L 2300/204 (2013.01); A61L 2430/14 (2013.01)

Citation (applicant) • US 6107495 A 20000822 - CAZAUX JEAN-BERNARD [FR], et al • US 6139870 A 20001031 - VERRECCHIA THIERRY [FR] • US 6440102 B1 20020827 - ARENBERG IRVING K [US], et al • US 6648873 B2 20031118 - ARENBERG MICHAEL H [US], et al • US 6120484 A 20000919 - SILVERSTEIN HERBERT [US] • US 4164559 A 19790814 - DUNN MICHAEL W [US], et al • US 4474752 A 19841002 - HASLAM JOHN L [US], et al • US 6911211 B2 20050628 - EINI MEIR [IL], et al • US 6377849 B1 20020423 - LENARZ THOMAS [DE], et al • US 33781506 A 20060124 • US 6648373 B2 20031118 - HAWES TIMOTHY R [US] • US 6911211 B2 20050628 - EINI MEIR [IL], et al • GENESTE ET AL., EUR. J MED., vol. 14, 1979, pages 301 - 08 • DAVID E. BUGAY: "Drugs and the Pharmaceutical Sciences", vol. 94, 1999, MARCEL DEKKER AG • RAYMOND ROWE, PAUL SHESKEY, AND SIAN OWEN: "Handbook of Pharmaceutical Excipients, 5TH ED.", 2006, APHA PUBLICATIONS • MARK GIBSON: "Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate Drug Selection to Commercial Dosage Form", 2004, INTERPHAM/CRC • KONISHI ET AL., ACTA OTOLARYNG, vol. 76, pages 410 - 418 • MORRIS ET AL., AM J OTOL, vol. 10, 1989, pages 148 - 9 • PRAKOBVAITAYAKIT ET AL., AAPS PHARMASCITECH, vol. 4, no. 4, 2003, pages E71 • ORIVE, CANCER THERAPY, vol. 3, 2005, pages 131 - 38 • LU ET AL., ADVDRUG DELIVREV, vol. 56, 2004, pages 1621 - 33 • RODRIGUES ET AL., PROC NATL ACAD SCI USA, vol. 100, 2003, pages 6087 - 92 • HANSEN ET AL., J PHYS CHEM, vol. 92, 1988, pages 2189 - 96 • FANG ET AL., BR J PHARMACOL, vol. 141, 2004, pages 508 - 16 • TAKIZAWA ET AL., CEREB BLOOD FLOW METAB, vol. 15, 1995, pages 611 - 8 • AGERMAN K; CANION B; DUAN M; EMFOTS P: "Neurotrophins, NMDA receptors, and nitric oxide in development and protection of the auditory system", ANN NY ACAD SCI, vol. 884, 1999, pages 131 - 42 • BUGAY. DE: "Pharmaceutical Excipients (Drugs and the Phramaceutical Sciences)", vol. 94, 1999, MARCEL DEKKER AG • BASILE AS; HUANG JM; XIE C; WEBSTER D; BERLIN C; SKOLNICK P: "N-methyl-D-aspartate .. antagonists limit aminoglycoside antibiotic- induced hearing loss", NATURE MEDICINE, vol. 2, 1996, pages 1338 - 43, XP002053270, DOI: doi:10.1038/nm1296-1338 • CALABRESI P; CENTONZE D; CUPINI LM; COSTA C; PISANI F; BEMARDI G: "Ionotropic glutamate receptors: still a target for nouroprotection in brain ischemia? Insights from in vitro studies", NEUROBIOL DIS, vol. 12, 2003, pages 82 - 8 • CHEN Z; ULFENDAHL M; RUAN R; TAN L; DUAN M: "Protection of auditory function against noise trauma with local caroverine administration in guinea pigs", HEAR RES, vol. 197, no. 13, 2004, pages 136 • CHEN Z; ULFENDAHL M; RUAN R; TAN L; DUAN M: "Acute treatmant of noise trauma with local caroverine application in the guinea pig", ACTA OTOLARYNGOL, vol. 1239, 2003, pages 05 - 909 • COSTA E: "From GABA receptor diversity emerges a unified vision of GABAergic inhibition", ANN REV PHARMACOL TOXICOL, vol. 38, 1998, pages 321 - 350 • CZUCZWAR SJ; PATSAOLS PN: "The new generation of GABA enhances. Potential in the treatment of epilepsy", CNS DRUGS, vol. 15, 2001, pages 339 - 350, XP001095132, DOI: doi:10.2165/00023210-200115050-00001 • DANYSZ W; ESSMANN U; BRESINK 1; WILKE R: "Glutamate antagonists have different effects on spontaneous locomotor activity in rats", PHARMACOL BIOCHEM BEHAV, vol. 48, 1994, pages 111 - 8, XP025538614, DOI: doi:10.1016/0091-3057(94)90506-1 • DANYSZ W; PARSONS CG: "Glycine and N-methyl-D-aspartate receptors: physiological significance and possibla therapeutic applications", PHARMACOLOGICAL REVIEWS, vol. 50, 1998, pages 597 - 664, XP001157576 • DANYSZ W; PARSONS CG: "Nauroprotective potential of ionotropic glutamate receptor antagonists", NEUROTOX RES, vol. 4, 2002, pages 119 - 26 • DUAN M; AGERMAN K; EMFORS P; CANLON B: "Complementary roles of neurotrophin 3 and a N-methyl-I)-asparate antagonist in the protection of noise and aminoglycoside-induced ototoxicity", PROO NATL ACAD SCI USA, vol. 91, 2000, pages 7597 - 602 • FELDBLUM S; ARNAUD S; SIMON M; RABIN 0, D; ARBLIGNY P: "Efficacy of a new neuroprotective agent, gacyclidine, In a model of rat spinal cord injury", J NEUROTRAUMA, vol. 17, 2000, pages 1079 - 93 • FENG B; TSE HW; SKIFTOR DA; MORLEY R; JANE DE; MONAGHAN DT: "Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-carbonyl) piperazine-2,3-dicarboxylic acid", BR J PHARMACOL, vol. 141, 2004, pages 508 - 516 • GALICI R; PINNA 0; STEPHENS DN; SCHNEIDER HH; TURSKI L: "Tolerance to and dependence on Alprazolam are due to changes in OABA receptor function and are independent of exposure to experimental set-up", RESTOR NEUROL NEUROSOI, vol. 12, 1998, pages 233 - 237 • GALLAGHER MJ; HUANG H; PRITCHETT DB; LYNCH DR: "Interactions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptor", J BIOL CHEM, vol. 271, 1996, pages 9603 - 11 • GENESTE P; KAMENSKA JM; UNG SN; HERRMANN P; GOUDAL R; TROUILLER G: "Determination conformationnelle de dérivés de la phencyclidine en vue dune corrdlation structure-activité", BUR J MED CHEM, vol. 14, 1979, pages 301 - 308 • GIBSON M: "Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate Drug Selection to Commercial Dosage Form", 2004, INTERPHARM/CRC • GINSKI MJ; WITKIN JM: "Sensitive and rapid behavioral differentiation of N-methyl-D-aspartate receptor antagonists", PSYCHOPHARMACOLOGY (BERL, vol. 114, 1994, pages 573 - 82 • GORDON RK; NIGAM SV; WEITZ JA; DAVE JR; DOCTOR BP; VED HS: "The NMDA receptor ion channel: a site for binding of Huperzine A", J APPL TOXICOL., vol. 21, no. 1, 2001, pages 84,7 - 51 • GUITTON MJ; WANG J; PUEL JL: "New pharmacological strategies to restore hearing and treat tinnitus", ACTA OTOLARYNGOL, vol. 124, 2004, pages 411 - 51 • HANSEN RE; TONSAGER MW: "Determination of the regime of mpid reacting systems in stopped. and steady-flow investigations by the velocity probe method", J PHYS CHEM, vol. 92, 1988, pages 2189 - 2196 • HERIN GA; DU S; AIZENMANE: "The neuroproteotive agent ebselen modifies NMDA receptor function via the redox modulatory site", J. NEUROCHEM, vol. 78, 2001, pages 1307 - 14, XP008139943, DOI: doi:10.1046/j.1471-4159.2001.00517.x • HERMANN A; VARGA V; JANAKY R; DOHOVICS R; SARANSAARI P; OJA SS: "Interference of ligands to ionotropic glutamate receptors in pig cerebral cortical synaptic membranes", NEUROCHEM RES, vol. 25, 2000, pages 1119 - 24 • HESSELINK MB; SMOLDERS H; DE BOER AG; BREIMER DD; DANYSZ W: "Modifications of the behavioral profile of non-competitive NMDA receptor antagonists, memantine, amantadine and (+) MK-801 after chronic administration", BEHAV PHARMACOL, vol. 10, 1999, pages 85 - 98 • HEWITT DJ: "The use of NMDA-receptor antagonists in the treatment of pain", CLIN J PAIN, vol. 16, 2000, pages 73 - 9 • IKONOMIDOU C; TURSKI L: "Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury", LANCET NEUROL, vol. 1, 2002, pages 383 - 6, XP004811329, DOI: doi:10.1016/S1474-4422(02)00164-3 • KOHL BK; DAMIHARDT G: "The NMDA receptor complex: a promising target for novel anti epileptic strategies", CURR MED CHEM, vol. 8, 2001, pages 1275 - 89 • KONISHI T; KELSEY E: "Effect of potassium deficiency on cochlear potentials and cation contents of the endolymph", ACTA OTOLARYNGOL, vol. 76, 1973, pages 410 - 8 • KOPKE RD; COLEMAN JK; LIU J; CAMPBELL KC; RIFFENBURGH RH: "Candidate's thesis: enhancing intrinsic cochtear stress defenses to reduce noise-induced hearing loss", LARYNGOSCOPE, vol. 112, 2002, pages 1515 - 32 • LU Y; CHEN SC: "Micro and nano-fabrication of biodegradable polymers for drug delivery", ADV DRUG DELIV REV, vol. 56, 2004, pages 1621 - 1633, XP004550360, DOI: doi:10.1016/j.addr.2004.05.002 • MORRISAW; MORRISON GA: "Cochlear dialysis fot Meniere's disease, An update", AM J. OTOL., vol. 10, 1989, pages 148 - 9, XP008020587 • LYNCH DR; GALLAGHER MJ: "Inhibition of N-methyl-D-aspartate receptors by haloperidol: developmental and pharmacological characterization in native and recombinant receptors", J PHARMACOL EXP THER, vol. 279, 1996, pages 154 - 61 • LYNCH DR; SHIM SS; SEIFERT KM; KURAPATHI S; MUTEL V; OALLAGHER MJ; GUTTMANN RP: "Pharmacological characterization of interaction of Ro 25-6981 with the NR2B (epsilon2) subunit", EUR J PHARMACOL, vol. 416, 2001, pages 185 - 95 • MAYER S; HARRIS BR; GIBSON DA; BLANCHARD JA; PRENDERGAST MA; HOLLEY RC; LITTLETON J: "Acamprosate, MK-801, and ifenprodil inhibit neurotoxioity and calcium entry induced by ethanol withdrawals in organotypic slice cultures from neonatal rat hippocampus", ALCOHOL CLIN EXP RES., vol. 26, 2002, pages 1468 - 78 • MUELLER AL; ARTMAN LD; BALANDRIN MF; BRADY E; CHIEN Y; DELMAR EG; GEORGE K; KIERSTEAD A; ARRIOTT TB; MOE ST: "NPS 1506, a novel NMDA receptor antagonist and neuroprotectant. Review of preclinical and clinical studies", ANN N Y ACAD SCI., vol. 890, 1999, pages 450 - 7 • MULY SM; GROSS JS; POTASHNER SJ: "Noise trauma alters D-[3H]aspartate release and AMPA binding in chinchilla cochlear nucleus", J NEUROSCI RES, vol. 75, 2004, pages 585 - 596 • NANKAI M; PAGE D; CARTER C: "NMDA receptor subtype selectivity: eliprodil, polyamine spidertoxins, dextromethorphan, and desipramine selectively block NMDA-evoked striatal acetylcholine but not spermidine release", J NEUROCHCM, vol. 64, 1995, pages 2043 - 8 • NINGARAJ NS; CHEN W; SCHLOSS JV; FAIMAN MD; WU JY: "S-methyl-N,N-diethylthiocarbamate sulfoxide elicits neuroprotective effect against N- methyl-D-aspartate receptor-mediated neurotoxicity", J BIOMED SCI., vol. 8, 2001, pages 104 - 13 • NORDANG L; OESTREICHER E; ARNOLD W; NNIKO M: "Glutamate is the afferent neurotransmitter in the human cochlea", ACTA OTO- LARYNGOLOGICA, vol. 120, 2000, pages 359 - 362 • OESTREICHER E; ARNOLD W; EHRENBERGER K; FELIX D: "Memantine suppresses the glutamatergic neurotransmission of mammalian inner hair cells", ORL J OTORHINOLARYNGOL RELAT SPEC, vol. 60, 1998, pages 18 - 21, XP009105375, DOI: doi:10.1159/000027556 • OESTREICHER E; ARNOLD W; EHRENBERGER K; FELIX D: "New approaches for inner-ear therapy with glutamate antagonists", ACTA OTO- LARYNGOLOGICA, vol. 119, 1999, pages 174 - 178 • OESTREICHER E; EHRENBERGER K; FELIX D: "Different action of memantine and caroverine on glutamatergic transmission in the mammalian cochlea", ADV OTORBINOLARYNGOL, vol. 59, 2002, pages 18 - 25 • OLIVER D; LUDWIG J; REISINGER E; ZOOLLNER W; RUPPERSBERG JP; FAKLER B: "Memantine inhibits efferent cholinergic transmission in the cochlea by blocking nicotinic acetylcholine receptors of the outer hair cells", MOL PHARMACOL, vol. 60, 2001, pages 183 - 189, XP001133753 • ORIVE 0; HERNÁNDEZ RM; GASCÓN AR; PEDRAZ JL: "Micro and nano drug delivery systems in cancer therapy", CANCER THERAPY, vol. 3, 2005, pages 131 - 138 • PALMER GC: "Neuroprotection by NMDA receptor antagonists in a variety of neuropathies", CURR DRUG TARGETS, vol. 2, 2001, pages 241 - 71, XP008003935, DOI: doi:10.2174/1389450013348335 • PARSONS CO; QUACK G; BRESINK I; BARAN L; PRZEGALINSKI E; KOSTOWSKI W; KRZASCIK P; HARTMANN S; DANYSZ W: "Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvuisive and motor impairment activity in vivo", NEUROPHANNACOLOGY, vol. 34, 1995, pages 1239 - 58 • PETERSON SL; PURVIS RS; GRIFFITH JW: "DifFerential neuroprotective effects of the NMDA receptor-associatad glycine site pardal agonists 1- aminocyclopropanecarboxylic acid (ACPC) and D-cycloserine in lithlum-pilocarpine status epilepticus", NEUROTOXICOLOGY, vol. 25, 2004, pages 835 - 47 • PETTY MA; WEINTRAUB PM; MAYNARD KI: "ACEA 1021: flip or flop", CNS DRUG REV, vol. 10, 2004, pages 337 - 48 • POPIK P; LAYER RT; SKOLNICK P: "The putative anti-addictive drug ibogaine is a competitive inhibitor of [3H]MK-801 binding to the NMDA receptor complex", PSYCHOPHARMACOLOGY (BERL, vol. 114, 1994, pages 672 - 4 • PRAKOBVAITAYAKIT M; NIMMANNIT U: "Optimization of polylactic-co-glycolic acid nanoparticles containing itraconizole using 23 factorial design", AAPS PHARMASCITECH, vol. 4, no. 4, 2003, pages E71, XP002538957 • PUJOL R; PUEL JI: "Excitotoxicity, synaptic repair, and functional recovery in the mammalian cochlea: a review of findings", ANN N Y ACAD SOI, vol. 884, 1999, pages 249 - 254, XP008054644, DOI: doi:10.1111/j.1749-6632.1999.tb08646.x • RODRIGUES CM; SOLA S; NAN Z; CASTRO RE; RIBEIRO PS; LOW WC; STEER CJ: "Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after Mute hemorrhagic stroke in rats", PROC NATL ACAD SCI USA, vol. 100, 2003, pages 6087 - 6092 • SCHWARZ; GIBBONS SE; GRAHAM SR; COLBRY NL; GUZZO PR; LE VD; VARTANIAN MG; KINSORA JJ; LETARSKI SM; LI Z: "Novel cyclopropyl beta-amino acid analogues of pregabalin and gabapentin that target the alpha2-delta protein", J MED CHEM, vol. 48, 2005, pages 3026 - 3035, XP002419676, DOI: doi:10.1021/jm0491086 • SEIDMAN MD; VAN DE WATER TR: "Pharmacologio manipulation of the labyrinth with novel and traditional agents delivered to the inner ear", EAR NOSE THROAT J, vol. 82, 2003, pages 276 - 280,282-3,287-8 • STAHL SM: "Anticonvulsants and relief of chronic pain: pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels", J CLIN PSYCHIATRY, vol. 65, 2004, pages 596 - 597 • SUGIMOTO M; UCHIDA I; MASHIMO T: "Local anaesthetics have different mechanisms and sites of action at the recombinant N-methyl-D-aspartate (NMDA) receptors", BR J PHARMACOL, vol. 38, 2003, pages 876 - 82 • TAKIZAWA S; MATSUSHIMA K; FUJITA H; NANRI K; OGAWA S; SHINOHARA Y: "A selective N-type calcium channel antagonist reduces extracellular glutamate release and infarct volume in focal cerebral ischemia", J CEREBRAL BLOOD FLOW METAB, vol. 15, 1995, pages 611 - 8 • TAYLOR CP: "Mechanisms of action ofgabapentin", REV NEUROL (PARIS, vol. 153, no. 1, 1997, pages S39 - S45 • DALLOS P, POPPER AN, FAY RR: "The Cochlea", 1996, SPRINGER, article WANGEMANN P; SCHACHT J: "Homeostatic mechanisms in the cochlea", pages: 130 - 185 • ZHOU ZL; CAI SX; WHITTEMORE ER; KONKOY CS; ESPITIA SA; TRAN M; ROOK DM; COUGHENOUR LL; HAWKINSON JE; BOXER PA: "4- Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist", J MED CHEM, vol. 42, 1999, pages 2993 - 3000, XP002201030, DOI: doi:10.1021/jm990246i • ZHOU LM; SZONDREI GI; FOSSOM LH; MACCECCHINI ML; SKOLNICK P; OTVO L JR: "Synthetic analogs of conantokin-G: NMDA antagonists acting through a novel polyamine-coupled site", J NEUROCHEM, vol. 66, 1996, pages 620 - 8, XP009004827

Citation (search report) • [E] WO 2007038949 A1 20070412 - AURIS MEDICAL AG [CH], et al • [XPI] WO 2005094799 A2 20051013 - AURIS MEDICAL AG [CH], et al • [E] WO 2007119098 A2 20071025 - AURIS MEDICAL AG [CH], et al • [Y] WO 03015699 A2 20030227 - EPICEPT CORP [US] • [XYI] US 6017961 A 20000125 - FLORES JOHN ANTHONY [US], et al • [Y] WO 2004022069 A1 20040318 - DURECT CORP [US], et al

Designated contracting state (EPC) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication) US 2006205789 A1 20060914; CN 101163481 A 20080416; EP 1861104 A2 20071205; EP 1861104 A4 20111214; EP 2932971 A1 20151021; JP 2008531726 A 20080814; US 2011136870 A1 20110609; US 2012208848 A1 20120816; WO 2006096518 A2 20060914; WO 2006096518 A3 20070322

DOCDB simple family (application) US 36772006 A 20060306; CN 200680013796 A 20060306; EP 06736872 A 20060306; EP 15000954 A 20060306; JP 2007558274 A 20060306; US 2006007622 W 20060306; US 201113021264 A 20110204; US 201213455736 A 20120425